PAQ: small molecules for autophagy-dependent degradation

With a July 15th $30 million series A round led by Sherpa Partners, PAQ joins a growing number of biotechs developing autophagy-dependent degraders that could push targeted degradation beyond protein substrates. 

PAQ Therapeutics Inc. is designing autophagosome-tethering compounds (ATTECs) in which one part of the molecule binds a component of the autophagy pathway and another part binds to a disease-causing substrate...